Journal of Clinical Endocrinology & Metabolism, Vol 78, 305-309, Copyright © 1994 by Endocrine Society

ARTICLES

Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome

G Tropeano, A Lucisano, I Liberale, A Barini, IP Vuolo, G Martino, E Menini and S Dell'Acqua
Department of Obstetrics and Gynecology, Universita Cattolica, del S. Guore, Rome, Italy.

We examined the effects of an oral glucose load on plasma insulin, androgens, and beta-endorphin (beta EP) concentrations in patients carefully selected as having polycystic ovary syndrome (PCOS) and normal glucose tolerance. Our aim was to verify whether insulin resistance is a common feature of PCOS and to differentiate the metabolic abnormalities related to PCOS from those associated with obesity. Plasma immunoreactive insulin (IRI), C-peptide (C-PR), testosterone, androstenedione, dehydroepiandrosterone sulfate, ACTH, and beta EP responses to a 3-h oral glucose tolerance test (OGTT) were evaluated in 10 obese (OB-PCOS) and 10 nonobese (NO-PCOS) patients with PCOS and in 7 obese and 7 nonobese ovulatory controls. OB-PCOS and NO- PCOS did not differ significantly from weight-matched controls in the IRI response, but had a significantly higher C-PR response in terms of mean postglucose load levels and mean incremental areas. During OGTT, mean plasma levels of testosterone, androstenedione, and dehydroepiandrosterone sulfate declined in both PCOS groups as well as in controls, and no significant correlation between the plasma androgen and IRI or C-PR responses was found. The ACTH response in OB-PCOS and NO-PCOS was similar to that in controls, with a progressive decrease until 180 min. A similar decline in plasma beta EP was found in controls, whereas no change in plasma beta EP was observed in OB-PCOS and NO-PCOS. These findings indicate that independently of the presence of obesity, PCOS patients have enhanced insulin secretion in response to OGTT and show a peculiar pattern of changes in plasma beta EP.

This article has been cited by other articles:

				M. O. Goodarzi, S. Erickson, S. C. Port, R. I. Jennrich, and S. G. Korenman {beta}-Cell Function: A Key Pathological Determinant in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 310 - 315. [Abstract] [Full Text] [PDF]

				J. Vrbikova, B. Bendlova, M. Hill, M. Vankova, K. Vondra, and L. Starka Insulin Sensitivity and {beta}-Cell Function in Women With Polycystic Ovary Syndrome Diabetes Care, July 1, 2002; 25(7): 1217 - 1222. [Abstract] [Full Text] [PDF]

				L. Ibáñez, J. DiMartino-Nardi, N. Potau, and P. Saenger Premature Adrenarche--Normal Variant or Forerunner of Adult Disease? Endocr. Rev., December 1, 2000; 21(6): 671 - 696. [Abstract] [Full Text]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				A.M. Fulghesu, F. Cucinelli, V. Pavone, F. Murgia, M. Guido, A. Caruso, S. Mancuso, and A. Lanzone Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome Hum. Reprod., March 1, 1999; 14(3): 611 - 617. [Abstract] [Full Text] [PDF]